Finally, given that SGLT-2 inhibitor use can exacerbate volume depletion via its diuretic effects, resulting in renal function decline during illness, guidelines from Diabetes Canada have integrated SGLT-2 inhibitors as one of the class of medications that should be stopped during acute illness (Figure 2) [8]. Here, SLC5A2 is linked to diabetes mellitus.